TriSalus Life Sciences, Inc. (Nasdaq: TLSI) will hold a conference call and webcast on March 5, 2026, to discuss its financial results for the quarter ended December 31, 2025, the company announced Wednesday.
The call is scheduled for 4:30 PM Eastern Time. A press release containing detailed financial results will be released prior to the call, according to the company. Interested parties can register for the call through an online form, with dial-in details to be provided via email after registration. The event will also be accessible via a live webcast on the investor relations section of TriSalus’ website, with a replay available afterward.
TriSalus Life Sciences is an oncology-focused medical technology company developing drug delivery technologies and immunotherapies for solid tumors. The company’s platform includes three FDA-cleared devices utilizing its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach: the TriNav® Infusion System, the TriNav Infusion System LV and the Pancreatic Retrograde Venous Infusion System. These devices are designed for hepatic arterial infusion of liver tumors and pancreatic tumors, respectively.
The PEDD technology aims to improve therapeutic delivery to tumors even as minimizing exposure to healthy tissue. TriSalus is also developing nelitolimod, an investigational immunotherapy designed to address the immunosuppressive tumor environment, particularly in the liver and pancreas. Clinical trial data from Pressure-Enabled Regional Immuno-Oncology™ (PERIO) trials suggest that nelitolimod delivered via PEDD may have positive immune effects.
According to stock information as of 9:34 AM EST on February 25, 2026, TriSalus Life Sciences stock (TLSI) was trading at $5.36, up $0.04 (0.75%) with a volume of 2,244 shares. The previous day’s closing price was $5.32, with a day’s high of $5.36.
TriSalus plans to initiate discussions with pharmaceutical partners regarding further clinical development of nelitolimod, with results from three Phase 1 studies expected in 2026.
